Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 02 2020
Historique:
received: 09 04 2019
accepted: 13 01 2020
entrez: 7 2 2020
pubmed: 7 2 2020
medline: 13 11 2020
Statut: epublish

Résumé

Chronic kidney disease (CKD) progresses to end-stage renal failure via renal tubulointerstitial fibrosis. Malnutrition, inflammation, and arteriosclerosis interact to exacerbate the poor prognosis of CKD, and their effective management is thus essential. The traditional Japanese medicine Rikkunshito (RKT) exerts appetite-stimulating effects via ghrelin, which attenuates inflammation and fibrosis. We evaluated the therapeutic effect of RKT in unilateral ureter obstruction (UUO)-induced renal fibrosis/inflammation and body weight loss in mice. UUO and sham-operated mice were fed a standard diet or diet containing 3.0% RKT. Renal fibrosis was investigated by histopathology and macrophage infiltration was determined by immunohistochemistry. Expression levels of genes associated with fibrosis, inflammation, ghrelin, and mitochondrial function were determined by quantitative reverse transcription-polymerase chain reaction and western blot analyses. RKT treatment partially prevented UUO-induced weight loss but failed to attenuate renal fibrosis and inflammation. Renal expression of sirtuin 1, a ghrelin-downstream signalling molecule, and gene expression of peroxisome proliferator-activated receptor-γ coactivator 1α and Bcl-2/adenovirus E1B interacting protein 3 were unaffected by RKT. These results indicate that RKT inhibits weight loss but does not improve renal fibrosis or inflammation in a rapidly progressive renal fibrosis mouse model. RKT may have a protective effect on weight loss associated with CKD.

Identifiants

pubmed: 32024850
doi: 10.1038/s41598-020-58214-0
pii: 10.1038/s41598-020-58214-0
pmc: PMC7002622
doi:

Substances chimiques

Drugs, Chinese Herbal 0
liu-jun-zi-tang 0
Sirtuin 1 EC 3.5.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1782

Références

Zyga, S., Christopoulou, G. & Malliarou, M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease. J. Ren Care 1, 12–5 (2011).
doi: 10.1111/j.1755-6686.2011.00201.x
Akdag, I. et al. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clin. Pract. 108, c99–c105 (2008).
doi: 10.1159/000113526
Nojiri, T. et al. Protective effects of ghrelin on cisplatin-induced nephrotoxicity in mice. Peptides 82, 85–91 (2016).
doi: 10.1016/j.peptides.2016.06.003
Takeda, H. et al. Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology 151, 244–252 (2010).
doi: 10.1210/en.2009-0633
Takeda, H. et al. Rikkunshito as a ghrelin enhancer. Methods Enzymol. 514, 333–351 (2012).
doi: 10.1016/B978-0-12-381272-8.00021-0
Meier, U. & Gressner, A. M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin. Chem. 50, 1511–1525 (2004).
doi: 10.1373/clinchem.2004.032482
Peeters, T. L. Ghrelin: a new player in the control of gastrointestinal functions. Gut 54, 1638–1649 (2005).
doi: 10.1136/gut.2004.062604 pubmed: 1774760 pmcid: 1774760
Delporte, C. Structure and physiological actions of ghrelin. Scientifica (Cairo). 2013, Article ID 518909, 25 pages (2013).
Fujimura, K. et al. Ghrelin protects against renal damages induced by angiotensin-II via an antioxidative stress mechanism in mice. PLoS One 9, e94373 (2014).
doi: 10.1371/journal.pone.0094373 pubmed: 3991592 pmcid: 3991592
Sun, G. X. et al. Ghrelin attenuates renal fibrosis and inflammation of obstructive nephropathy. J. Urol. 193, 2107–2115 (2015).
doi: 10.1016/j.juro.2014.11.098 pubmed: 25481038 pmcid: 25481038
Azushima, K. et al. Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice. Sci. Rep. 9, 6201 (2019).
doi: 10.1038/s41598-019-42657-1 pubmed: 30996242 pmcid: 30996242
Matsuda, M. et al. Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein. J. Biol. Chem. 288, 19238–19249 (2013).
doi: 10.1074/jbc.M113.451054 pubmed: 23653383 pmcid: 23653383
Matsuda, M. et al. Involvement of Runx3 in the basal transcriptional activation of the mouse angiotensin II type 1 receptor-associated protein gene. Physiol. Genomics 43, 884–894 (2011).
doi: 10.1152/physiolgenomics.00005.2011 pubmed: 21586669 pmcid: 21586669
Kobayashi, R. et al. An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model. Kidney Int. 91, 1115–1125 (2017).
doi: 10.1016/j.kint.2016.10.035 pubmed: 28081856 pmcid: 28081856
Ohsawa, M. et al. Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension. Kidney Int. 86, 570–581 (2014).
doi: 10.1038/ki.2014.95 pubmed: 4149871 pmcid: 4149871
Azushima, K. et al. Adipocyte-specific enhancement of angiotensin II type 1 receptor-associated protein ameliorates diet-induced visceral obesity and insulin resistance. J. Am. Heart Assoc. 6, e004488 (2017).
doi: 10.1161/JAHA.116.004488 pubmed: 5524000 pmcid: 5524000
Maeda, A. et al. Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesity. J. Am. Heart Assoc. 2, e000312 (2013).
doi: 10.1161/JAHA.113.000312 pubmed: 3828814 pmcid: 3828814
Uneda, K. et al. Angiotensin II type 1 receptor-associated protein regulates kidney aging and lifespan independent of angiotensin. J. Am. Heart Assoc. 6, e006120 (2017).
doi: 10.1161/JAHA.117.006120 pubmed: 5586453 pmcid: 5586453
Kong, W. et al. Renal Fibrosis, Immune Cell Infiltration and Changes of TRPC Channel Expression after Unilateral Ureteral Obstruction in Trpc6−/− Mice. Cell Physiol Biochem. 52, 1484–1502 (2019).
Haruhara, K. et al. Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile. Atherosclerosis 269, 236–244 (2018).
doi: 10.1016/j.atherosclerosis.2018.01.013
Wakui, H. et al. Enhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertension. Hypertension 61, 1203–1210 (2013).
doi: 10.1161/HYPERTENSIONAHA.111.00572 pubmed: 3657390 pmcid: 3657390
Ohki, K. et al. Angiotensin II type 1 receptor-associated protein inhibits angiotensin II-induced insulin resistance with suppression of oxidative stress in skeletal muscle tissue. Sci. Rep. 8, 2846 (2018).
doi: 10.1038/s41598-018-21270-8 pubmed: 5809432 pmcid: 5809432
Zhang, W. et al. Greater Physiological and Behavioral Effects of Interrupted Stress Pattern Compared to Daily Restraint Stress in Rats. PLoS One. 9, e0102247 (2014).
Larder, R. et al. Obesity-associated gene TMEM18 has a role in the central control of appetite and body weight regulation. Proc Natl Acad Sci USA 114, 9421–9426 (2017).
doi: 10.1073/pnas.1707310114
Fappi, A. et al. The effects of omega-3 fatty acid supplementation on dexamethasone-induced muscle atrophy. Biomed Res Int. 2014, 961438 (2014).
doi: 10.1155/2014/961438 pubmed: 4055633 pmcid: 4055633
Chen, V. P. et al. Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling. Proc Natl Acad Sci USA 114, 10960–10965 (2017).
doi: 10.1073/pnas.1706517114
Takeda, H. et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 134, 2004–2013 (2008).
doi: 10.1053/j.gastro.2008.02.078
Matsumura, T. et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J. Gastroenterol. 45, 300–307 (2010).
doi: 10.1007/s00535-009-0166-z
Cui, H., López, M. & Rahmouni, K. The cellular and molecular bases of leptin and ghrelin resistance in obesity. Nat. Rev. Endocrinol. 13, 338–351 (2017).
doi: 10.1038/nrendo.2016.222
Terawaki, K. et al. Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model. PLoS One 12, e0173113 (2017).
doi: 10.1371/journal.pone.0173113 pubmed: 5332064 pmcid: 5332064
Fujitsuka, N. et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry 1, e23 (2011).
doi: 10.1038/tp.2011.25 pubmed: 22832525 pmcid: 22832525
Fujitsuka, N. et al. Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front. Pharmacol. 5, 271 (2014).
doi: 10.3389/fphar.2014.00271 pubmed: 25540621 pmcid: 25540621
Kovesdy, C. P. et al. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am. J. Kidney Dis. 49, 581–91 (2007).
doi: 10.1053/j.ajkd.2007.02.277 pubmed: 17472839 pmcid: 17472839
Pereira, R. A. et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol. Dial. Transplant. 30, 1718–25 (2015).
doi: 10.1093/ndt/gfv133 pubmed: 25999376 pmcid: 25999376
Fahal, I. H. Uraemic sarcopenia: aetiology and implications. Nephrol. Dial. Transplant. 29, 1655–65 (2014).
doi: 10.1093/ndt/gft070 pubmed: 23625972 pmcid: 23625972
Sato, E. et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci. Rep. 6, 36618 (2016).
doi: 10.1038/srep36618 pubmed: 27830716 pmcid: 27830716
Fujitsuka, N. et al. Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1. Mol. Psychiatry 21, 1613–1623 (2016).
doi: 10.1038/mp.2015.220 pubmed: 26830139 pmcid: 26830139
Shimada, T. et al. Des-acyl ghrelin protects microvascular endothelial cells from oxidative stress-induced apoptosis through sirtuin 1 signaling pathway. Metabolism 63, 469–474 (2014).
doi: 10.1016/j.metabol.2013.12.011 pubmed: 24486147 pmcid: 24486147
Yang, S. Y. et al. A low-salt diet increases the expression of renal sirtuin 1 through activation of the ghrelin receptor in rats. Sci. Rep. 6, 32787 (2016).
doi: 10.1038/srep32787 pubmed: 27600292 pmcid: 27600292
Tang, B. L. Sirt1 and the mitochondria. Mol. Cells 39, 87–95 (2016).
doi: 10.14348/molcells.2016.2318 pubmed: 4757807 pmcid: 4757807
Stenvinkel, P. & Larsson, T. E. Chronic kidney disease: a clinical model of premature aging. Am. J. Kidney Dis. 62, 339–351 (2013).
doi: 10.1053/j.ajkd.2012.11.051
Yakabi, K. et al. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regul. Pept. 161, 97–105 (2010).
doi: 10.1016/j.regpep.2010.02.003
Huang, L. et al. Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra 3, 12–29 (2013).
doi: 10.1159/000346180 pubmed: 3617971 pmcid: 3617971
Jadot, I. et al. An integrated view of aristolochic acid nephropathy: Update of the literature. Int. J. Mol. Sci. 18, E297 (2017).
doi: 10.3390/ijms18020297
Jia, T. et al. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol. 14, 116 (2013).
doi: 10.1186/1471-2369-14-116 pubmed: 3682934 pmcid: 3682934

Auteurs

Hiromichi Wakui (H)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. hiro1234@yokohama-cu.ac.jp.

Takahiro Yamaji (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kengo Azushima (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. azushima@yokohama-cu.ac.jp.
Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore, Singapore. azushima@yokohama-cu.ac.jp.

Kazushi Uneda (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kotaro Haruhara (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Akiko Nakamura (A)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kohji Ohki (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Sho Kinguchi (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Ryu Kobayashi (R)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Shingo Urate (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Toru Suzuki (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Daisuke Kamimura (D)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Shintaro Minegishi (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Tomoaki Ishigami (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Tomohiko Kanaoka (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kohei Matsuo (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Tomoyuki Miyazaki (T)

Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Tetsuya Fujikawa (T)

Center for Health Service Sciences, Yokohama National University, Yokohama, Japan.

Akio Yamashita (A)

Department of Molecular Biology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kouichi Tamura (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH